Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Anti-tumor treatment and healthcare consumption near death in the era of novel treatment options for patients with melanoma brain metastases.

BMC cancer - 5 Mar 2022

Eggen Annemarie C, Hospers Geke A P, Bosma Ingeborg, Kramer Miranda C A, Reyners Anna K L, Jalving Mathilde

Abstract excerpt

BACKGROUND: Effective systemic treatments have revolutionized the management of patients with metastatic melanoma, including those with brain metastases. The extent to which these treatments influence disease trajectories close to death is unknown. Therefore, this study aimed to gain insight into provided treatments and healthcare consumption during the last 3 months of life in patients with melanoma brain...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antineoplastic Agents
Share to Brain Neoplasms

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Hospitalization

Share to Melanoma

Share to Netherlands

Share to Patient Acceptance of Health Care

Share to Proto-Oncogene Proteins B-raf

Share to Treatment Outcome

Source

Open in PubMed Open full text

Identifiers

PMID: 35247992
DOI: 10.1186/s12885-022-09316-7
PMCID: PMC8897874

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Anti-tumor treatment and healthcare consumption near death in the era of novel treatment options for patients with melanoma brain metastases.PMID 35247992Read ↗

Real-World Evaluation of the Management, Treatment Pathways and Outcome of Melanoma Patients with Target Therapies in Italy.Semantic proximity Read ↗

The Prognostic Value of BRAF, C-KIT, and NRAS Mutations in Melanoma Patients With Brain Metastases.Semantic proximity Read ↗

Long-term survival of patients with advanced melanoma treated with BRAF-MEK inhibitors.Semantic proximity Read ↗

Systemic therapies for melanoma brain metastases: which drug for whom and when?Semantic proximity Read ↗

Tolerance and Effectiveness of Targeted Therapies in Aged Patients with Metastatic MelanomaSemantic proximity Read ↗

Survival in adult patients with BRAFV600 mutation-positive advanced melanoma: a noninterventional ambispective study of patients with cobimetinib combined with vemurafenib during the French early access program: MELANIS study.Semantic proximity Read ↗

Impact of BRAF inhibitors on surgical outcomes in melanoma brain metastases: Evidence from a multicenter observational study.Semantic proximity Read ↗

Recommended first-line management of brain metastases from melanoma: A multicenter survey of clinical practice.Semantic proximity Read ↗

Upfront targeted therapy for symptomatic melanoma brain metastases: paradigm changing?Semantic proximity Read ↗

Dabrafenib plus trametinib in patients with BRAFV600-mutant melanoma brain metastases (COMBI-MB): a multicentre, multicohort, open-label, phase 2 trial.Semantic proximity Read ↗

Nationwide Outcomes of Advanced Melanoma According to BRAFV600 Status.Semantic proximity Read ↗

Characterization of plasma circulating small extracellular vesicles in patients with metastatic solid tumors and newly diagnosed brain metastasisSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.